(SPRO) Spero Therapeutics - Ratings and Ratios
Antibiotics, Rare Disease Treatments, Carbapenem-Class Medication
SPRO EPS (Earnings per Share)
SPRO Revenue
Description: SPRO Spero Therapeutics
Spero Therapeutics Inc (NASDAQ:SPRO) is a clinical-stage biopharmaceutical company focused on developing novel treatments for multi-drug resistant bacterial infections and rare diseases. The companys pipeline includes tebipenem HBr, an oral antibiotic in Phase 3 development for complicated urinary tract infections, and SPR720, a potential first-line treatment for nontuberculous mycobacterial pulmonary disease.
From a business perspective, Spero Therapeutics has established strategic partnerships with Meiji Seika Pharma Co., Ltd., Everest Medicines, and Vertex Pharmaceuticals Incorporated to support the development and commercialization of its product candidates. These collaborations not only provide financial support but also validate the potential of Speros pipeline.
To evaluate the companys performance, key performance indicators (KPIs) such as cash runway, research and development (R&D) expenses, and pipeline progress are crucial. As a clinical-stage company, Speros cash burn rate is likely high due to ongoing R&D activities. Investors should monitor the companys cash reserves and R&D expenses to ensure they have sufficient resources to advance their pipeline. Additionally, the progress of tebipenem HBr and SPR720 through clinical trials will be critical in determining the companys future prospects.
From a financial perspective, Spero Therapeutics has a market capitalization of approximately $170 million, with a negative P/E ratio due to the companys current lack of profitability. Return on Equity (RoE) is also negative, indicating that the company is not generating returns on shareholder equity. As the company advances its pipeline and potentially brings products to market, these metrics are expected to improve.
Overall, Spero Therapeutics success will depend on its ability to advance its pipeline through clinical trials, secure additional funding or partnerships, and ultimately bring its products to market. Investors should closely monitor the companys progress, cash reserves, and R&D expenses to assess its potential for future growth.
SPRO Stock Overview
| Market Cap in USD | 105m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2017-11-02 |
SPRO Stock Ratings
| Growth Rating | -26.2% |
| Fundamental | 23.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 35.6% |
| Analyst Rating | 3.33 of 5 |
SPRO Dividends
Currently no dividends paidSPRO Growth Ratios
| Growth Correlation 3m | -87.7% |
| Growth Correlation 12m | 22.2% |
| Growth Correlation 5y | -70.9% |
| CAGR 5y | -30.42% |
| CAGR/Max DD 5y | -0.31 |
| Sharpe Ratio 12m | -0.41 |
| Alpha | 54.28 |
| Beta | 0.383 |
| Volatility | 56.03% |
| Current Volume | 175.5k |
| Average Volume 20d | 417k |
| Stop Loss | 2 (-7%) |
| Signal | -0.29 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-54.5m TTM) > 0 and > 6% of Revenue (6% = 2.43m TTM) |
| FCFTA -0.38 (>2.0%) and ΔFCFTA -15.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 109.8% (prev 71.23%; Δ 38.54pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.52 (>3.0%) and CFO -32.3m > Net Income -54.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.97 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (56.0m) change vs 12m ago 3.83% (target <= -2.0% for YES) |
| Gross Margin 87.50% (prev 99.66%; Δ -12.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 38.21% (prev 71.74%; Δ -33.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -39.77
| (A) 0.72 = (Total Current Assets 59.4m - Total Current Liabilities 14.9m) / Total Assets 62.1m |
| (B) -7.65 = Retained Earnings (Balance) -475.2m / Total Assets 62.1m |
| warn (B) unusual magnitude: -7.65 — check mapping/units |
| (C) -0.37 = EBIT TTM -39.3m / Avg Total Assets 106.0m |
| (D) -16.22 = Book Value of Equity -475.1m / Total Liabilities 29.3m |
| Total Rating: -39.77 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 23.64
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -25.98% = -5.0 |
| 3. FCF Margin -57.88% = -7.50 |
| 4. Debt/Equity 0.49 = 2.38 |
| 5. Debt/Ebitda -0.41 = -2.50 |
| 6. ROIC - WACC -95.35% = -12.50 |
| 7. RoE -122.2% = -2.50 |
| 8. Rev. Trend 27.13% = 1.36 |
| 9. Rev. CAGR 138.4% = 2.50 |
| 10. EPS Trend -23.90% = -0.60 |
| 11. EPS CAGR 57.80% = 2.50 |
What is the price of SPRO shares?
Over the past week, the price has changed by +3.86%, over one month by +1.42%, over three months by -16.02% and over the past year by +61.65%.
Is Spero Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SPRO is around 1.66 USD . This means that SPRO is currently overvalued and has a potential downside of -22.79%.
Is SPRO a buy, sell or hold?
- Strong Buy: 0
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SPRO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4 | 86% |
| Analysts Target Price | 4 | 86% |
| ValueRay Target Price | 1.8 | -14.9% |
Last update: 2025-08-26 02:47
SPRO Fundamental Data Overview
CCE Cash And Equivalents = 31.2m USD (Cash And Short Term Investments, last quarter)
P/S = 2.1664
P/B = 3.2056
Beta = 1.388
Revenue TTM = 40.5m USD
EBIT TTM = -39.3m USD
EBITDA TTM = -39.4m USD
Long Term Debt = 14.3m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.84m USD (from shortTermDebt, last quarter)
Debt = 16.2m USD (Calculated: Short Term 1.84m + Long Term 14.3m)
Net Debt = -27.6m USD (from netDebt column, last quarter)
Enterprise Value = 90.2m USD (105.2m + Debt 16.2m - CCE 31.2m)
Interest Coverage Ratio = unknown (Ebit TTM -39.3m / Interest Expense TTM 0.0)
FCF Yield = -25.98% (FCF TTM -23.4m / Enterprise Value 90.2m)
FCF Margin = -57.88% (FCF TTM -23.4m / Revenue TTM 40.5m)
Net Margin = -134.5% (Net Income TTM -54.5m / Revenue TTM 40.5m)
Gross Margin = 87.50% ((Revenue TTM 40.5m - Cost of Revenue TTM 5.06m) / Revenue TTM)
Tobins Q-Ratio = -0.19 (set to none) (Enterprise Value 90.2m / Book Value Of Equity -475.1m)
Interest Expense / Debt = 5.94% (Interest Expense 961.0k / Debt 16.2m)
Taxrate = 21.0% (US default)
NOPAT = -39.3m (EBIT -39.3m, no tax applied on loss)
Current Ratio = 3.97 (Total Current Assets 59.4m / Total Current Liabilities 14.9m)
Debt / Equity = 0.49 (Debt 16.2m / last Quarter total Stockholder Equity 32.8m)
Debt / EBITDA = -0.41 (Net Debt -27.6m / EBITDA -39.4m)
Debt / FCF = -0.69 (Debt 16.2m / FCF TTM -23.4m)
Total Stockholder Equity = 44.6m (last 4 quarters mean)
RoA = -87.68% (Net Income -54.5m, Total Assets 62.1m )
RoE = -122.2% (Net Income TTM -54.5m / Total Stockholder Equity 44.6m)
RoCE = -66.79% (Ebit -39.3m / (Equity 44.6m + L.T.Debt 14.3m))
RoIC = -88.29% (NOPAT -39.3m / Invested Capital 44.6m)
WACC = 7.06% (E(105.2m)/V(121.4m) * Re(7.43%)) + (D(16.2m)/V(121.4m) * Rd(5.94%) * (1-Tc(0.21)))
Shares Correlation 5-Years: 100.0 | Cagr: 14.91%
Discount Rate = 7.43% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -23.4m)
Revenue Correlation: 27.13 | Revenue CAGR: 138.4%
Rev Growth-of-Growth: -94.25
EPS Correlation: -23.90 | EPS CAGR: 57.80%
EPS Growth-of-Growth: -39.11
Additional Sources for SPRO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle